December 1, 2016 - By Adrian Mccoy · 0 Comments
The stock of Delmar Pharmaceuticals Incorporated (NASDAQ:DMPI) registered an increase of 63.52% in short interest. DMPI’s total short interest was 50,200 shares in December as published by FINRA. Its up 63.52% from 30,700 shares, reported previously. With 66,200 shares average volume, it will take short sellers 1 days to cover their DMPI’s short positions. The stock increased 1.00% or $0.04 on November 30, hitting $4.04. DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has risen 231.15% since April 28, 2016 and is uptrending. It has outperformed by 225.22% the S&P500.
DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The company has a market cap of $42.42 million. The Firm focuses on the treatment of cancer. It currently has negative earnings. The Firm is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme , a form of brain cancer.
DelMar Pharmaceuticals, Inc., incorporated on June 24, 2009, is a clinical-stage drug development company. The Firm focuses on the treatment of cancer. The Firm is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. The Company’s drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications.
More notable recent DelMar Pharmaceuticals Inc (NASDAQ:DMPI) news were published by: Prnewswire.com which released: “DelMar Pharmaceuticals Delivers an Address and Presents an Overview of …” on November 21, 2016, also Prnewswire.com with their article: “DelMar Pharmaceuticals Presents New VAL-083 Data at Two International …” published on November 07, 2016, Prnewswire.com published: “DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations” on October 13, 2016. More interesting news about DelMar Pharmaceuticals Inc (NASDAQ:DMPI) were released by: Prnewswire.com and their article: “DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical …” published on April 19, 2016 as well as Prnewswire.com‘s news article titled: “DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and …” with publication date: June 06, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy